Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,525.00-0.34%ETH$2,695.17-0.69%GOLD$4,192.70+0.86%OIL$89.91+0.54%
Smart Investors Daily
SID Premium
EQ

NASDAQ · EQ

Equillium, Inc. Common Stock

Healthcare · Biotechnology

$1.45

Down-$0.02 (-1.38%)

Updated Oct 6, 2026, 6:00 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.6M
P/E ratio
-3.58
Dividend yield
0.00%
52-week range
$0.76 – $3.54
Volume
795.62K
Avg. volume
570.19K

Price performance · EQ

EQ price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

EQ closed at $1.45 after 20 trading sessions, down 39.83% for the selected period.

Last close
$1.45
Period change
-39.83%
Period low
$1.41
Period high
$2.56
Daily close
View OHLC price history
EQ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.37$1.455$1.30$1.45795.62K
Oct 2, 2026$1.55$1.60$1.375$1.41934.79K
Oct 1, 2026$1.67$1.67$1.525$1.54529.4K
Sep 30, 2026$1.63$1.655$1.58$1.6253.1M
Sep 29, 2026$1.68$1.72$1.61$1.62316.29K
Sep 28, 2026$1.65$1.715$1.63$1.68241.73K
Sep 25, 2026$1.70$1.71$1.66$1.67137.75K
Sep 24, 2026$1.72$1.74$1.65$1.72280.74K
Sep 23, 2026$1.91$1.91$1.69$1.75504.6K
Sep 22, 2026$1.90$1.95$1.81$1.933.07M
Sep 21, 2026$1.98$1.98$1.85$1.895266.47K
Sep 18, 2026$1.89$1.995$1.8603$1.92853.47K
Sep 17, 2026$1.90$1.95$1.80$1.89708.08K
Sep 16, 2026$2.05$2.06$1.85$1.855770.25K
Sep 15, 2026$2.09$2.09$2.01$2.05231.49K
Sep 14, 2026$2.10$2.145$2.055$2.095261.9K
Sep 11, 2026$2.46$2.46$2.11$2.11554.05K
Sep 10, 2026$2.54$2.69$2.41$2.42397.61K
Sep 9, 2026$2.41$2.56$2.331$2.561.09M
Sep 8, 2026$2.20$2.47$2.17$2.41597.9K

Latest EQ news

The latest Smart Investors Daily articles mentioning EQ.

Stock researchCompany · Overview

EQ research

Overview

Company profile and research snapshot.

Company profile

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.00
Implied upside
—
Analysts
—
EQ recent ratings
DateFirmRatingTarget
Sep 4, 2026Roth CapitalBuy—
Jul 13, 2026Piper SandlerOverweight—
Jun 2, 2026Roth CapitalBuy—
May 28, 2026Roth CapitalBuy—
May 28, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Equillium Announces Poster Presentations at the 7th International AHR Conference

New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulationLA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portug

Yahoo · Sep 27, 2026

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined the company’s plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat. Connelly said t

Yahoo · Sep 16, 2026

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By